Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RYTM
RYTM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RYTM News
Rhythm Pharmaceuticals Receives EMA Support for Imcivree Label Expansion
4d ago
seekingalpha
Rhythm Pharmaceuticals Receives Positive EMA Opinion for IMCIVREE Expansion
4d ago
Newsfilter
PANTHERx Selected as Exclusive U.S. Pharmacy Partner for IMCIVREE Distribution
Mar 20 2026
PRnewswire
PANTHERx Selected as Exclusive U.S. Pharmacy Partner for IMCIVREE Distribution
Mar 20 2026
Newsfilter
U.S. Stocks Decline Amid Rising Energy Costs and Inflation Fears
Mar 20 2026
NASDAQ.COM
US Stocks Decline Amid Iran War Concerns
Mar 20 2026
NASDAQ.COM
Rhythm Pharmaceuticals Secures FDA Label Expansion for Setmelanotide
Mar 20 2026
seekingalpha
FDA Approves IMCIVREE for Hypothalamic Obesity Treatment
Mar 20 2026
NASDAQ.COM
Rhythm Pharmaceuticals' Lead Candidate Fails Key Clinical Trial Goal
Mar 17 2026
seekingalpha
Rhythm Pharmaceuticals Releases EMANATE Trial Results for Setmelanotide
Mar 17 2026
NASDAQ.COM
Rhythm Pharmaceuticals Reports Positive Phase 3 Trial Data for Setmelanotide
Mar 02 2026
Benzinga
Rhythm Pharmaceuticals Reports Positive Phase 3 Results for Obesity Treatment
Mar 02 2026
NASDAQ.COM
Rhythm Pharmaceuticals Reports Positive Data on Weight Loss Therapy Setmelanotide
Mar 01 2026
Newsfilter
RYTM Stock 52-Week Highs and Lows Analysis
Feb 27 2026
NASDAQ.COM
Rhythm Pharmaceuticals Reports Strong Q4 Results Exceeding Expectations
Feb 27 2026
Benzinga
Rhythm Pharmaceuticals Q4 2025 Earnings Call Highlights
Feb 26 2026
seekingalpha
Show More News
